trending Market Intelligence /marketintelligence/en/news-insights/trending/tbihgfsm08hmapujy444wa2 content esgSubNav
In This List

Antibe, Kwang Dong Pharmaceutical partner to develop anti-inflammatory drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Antibe, Kwang Dong Pharmaceutical partner to develop anti-inflammatory drug

Antibe Therapeutics Inc. and Kwang Dong Pharmaceutical Co. Ltd. signed a licensing deal to develop and commercialize anti-inflammatory drug ATB-346 in South Korea.

Under the agreement, Antibe will get C$13 million in development and commercial milestone payments, including C$1.3 million in up-front payment. The company will also receive a double-digit royalty on the South Korean net sales of the medicine, once commercialized.

ATB-346 is an anti-inflammatory drug being developed by Antibe to prevent ulcers and bleeding in the gastrointestinal tract due to non-steroidal anti-inflammatory drugs. The company has completed a phase 2b gastrointestinal safety study of the drug, in which ATB-346 was shown to be safer for the gastrointestinal tract than naproxen, a nonsteroidal anti-inflammatory drug that is widely used for treating pain but is associated with causing gastrointestinal ulceration and bleeding.

The Toronto-based company intends to begin a phase 2b dose-ranging efficacy study of the drug in September.

MedCI LLC acted as adviser on the transaction.